Olema制药（股票代码：OLMA）周三盘中大涨5.26%，延续了本周的强劲涨势。这波涨势主要受到竞争对手罗氏公司的口服乳腺癌药物在晚期临床试验中取得积极结果的提振。
周二，Olema股价飙升136%，创下四年来新高。尽管周三早盘公司宣布以19美元的价格发行1000万股新股，筹资1.9亿美元，但投资者情绪仍然高涨。公司计划将募集资金用于其主打产品帕拉雌酯（palazestrant）和OP-3136的持续临床开发。
分析师对Olema保持乐观态度。根据LSEG数据，所有9位跟踪该股的分析师均给予"买入"评级，目标价中位数为31美元，远高于当前交易价格。这表明市场认为该公司在乳腺癌治疗领域具有巨大潜力，尽管面临融资稀释，但长期前景依然看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.